{ "instance": { "nbio_10k.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 130, "dts": { "calculationLink": { "local": [ "nbio-20220331_cal.xml" ] }, "definitionLink": { "local": [ "nbio-20220331_def.xml" ] }, "inline": { "local": [ "nbio_10k.htm" ] }, "labelLink": { "local": [ "nbio-20220331_lab.xml" ] }, "presentationLink": { "local": [ "nbio-20220331_pre.xml" ] }, "schema": { "local": [ "nbio-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 411, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 22, "http://nascentbiotechinc.com/20220331": 15, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 42 }, "keyCustom": 120, "keyStandard": 175, "memberCustom": 30, "memberStandard": 15, "nsprefix": "nbio", "nsuri": "http://nascentbiotechinc.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://nascentbiotechinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://nascentbiotechinc.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - LICENSE SETTLEMENT", "role": "http://nascentbiotechinc.com/role/LicenseSettlement", "shortName": "LICENSE SETTLEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - EQUITY", "role": "http://nascentbiotechinc.com/role/EQUITY", "shortName": "EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - OPTIONS", "role": "http://nascentbiotechinc.com/role/OPTIONS", "shortName": "OPTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - WARRANTS", "role": "http://nascentbiotechinc.com/role/WARRANTS", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - INCOME TAXES", "role": "http://nascentbiotechinc.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - CONVERTIBLE DEBT", "role": "http://nascentbiotechinc.com/role/ConvertibleDebt", "shortName": "CONVERTIBLE DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - LICENSE AGREEMENT", "role": "http://nascentbiotechinc.com/role/LicenseAgreement", "shortName": "LICENSE AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://nascentbiotechinc.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - SUBSEQUENT EVENTS", "role": "http://nascentbiotechinc.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:SummarizesOfChangeInTheFairValueOfTheDerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:SummarizesOfChangeInTheFairValueOfTheDerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:ScheduleOfSharesEarnedByRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "role": "http://nascentbiotechinc.com/role/RelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:ScheduleOfSharesEarnedByRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - OPTIONS (Tables)", "role": "http://nascentbiotechinc.com/role/OptionsTables", "shortName": "OPTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:ScheduleOfSummaryOfWarrantsOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - WARRANTS (Tables)", "role": "http://nascentbiotechinc.com/role/WarrantsTables", "shortName": "WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:ScheduleOfSummaryOfWarrantsOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - INCOME TAXES (Tables)", "role": "http://nascentbiotechinc.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2014-07-15_nbio_JinEnGroupInternationalHoldingCompanyMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative)", "role": "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "shortName": "ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2014-07-15_nbio_JinEnGroupInternationalHoldingCompanyMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:SummarizesOfChangeInTheFairValueOfTheDerivativeLiabilities", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2021-03-31_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:SummarizesOfChangeInTheFairValueOfTheDerivativeLiabilities", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2020-03-31_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31_srt_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31_srt_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - GOING CONCERN (Details Narrative)", "role": "http://nascentbiotechinc.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:ScheduleOfAnnualSalaryAndAnnualSeveranceAmountsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:FiscalYearAnnualizedCompensationBeingPaid", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:ScheduleOfAnnualSalaryAndAnnualSeveranceAmountsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:FiscalYearAnnualizedCompensationBeingPaid", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:ScheduleOfSharesEarnedByRelatedPartyTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:InitialShareAwardsUnderContracts", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - RELATED PARTY TRANSACTIONS (Details 1)", "role": "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1", "shortName": "RELATED PARTY TRANSACTIONS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:ScheduleOfSharesEarnedByRelatedPartyTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:InitialShareAwardsUnderContracts", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "nbio:CashPaid", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - LICENSE SETTLEMENT (Details Narrative)", "role": "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative", "shortName": "LICENSE SETTLEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LifeSettlementContractsDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2017-10-01to2017-10-12_nbio_ConsultingAgreementMember", "decimals": "INF", "lang": null, "name": "nbio:NumberOfInstallmentsRemainingLiability", "reportCount": 1, "unique": true, "unitRef": "Integer", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2020-04-01to2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanSettlementsBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - EQUITY (Details Narrative)", "role": "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "shortName": "EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2020-04-01to2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanSettlementsBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptionsBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - OPTIONS (Details)", "role": "http://nascentbiotechinc.com/role/OptionsDetails", "shortName": "OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptionsBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:CommonStockExercisableTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - OPTIONS (Details Narrative)", "role": "http://nascentbiotechinc.com/role/OptionsDetailsNarrative", "shortName": "OPTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:CommonStockExercisableTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:ScheduleOfSummaryOfWarrantsOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2020-04-01to2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:ShareBasedCompensationArrangementGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - WARRANTS (Details)", "role": "http://nascentbiotechinc.com/role/WarrantsDetails", "shortName": "WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nbio:ScheduleOfSummaryOfWarrantsOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2020-04-01to2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:ShareBasedCompensationArrangementGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "nbio:WarrantsTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2020-04-01to2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:DeemedDividendFromDownRound", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - WARRANTS (Details Narrative)", "role": "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative", "shortName": "WARRANTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nbio:WarrantsTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2020-04-01to2021-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:DeemedDividendFromDownRound", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - INCOME TAXES (Details)", "role": "http://nascentbiotechinc.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://nascentbiotechinc.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - CONVERTIBLE DEBT (Details Narrative)", "role": "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "shortName": "CONVERTIBLE DEBT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2022-03-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "nbio:LicenseAgreementTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31_nbio_BioRayPharmaceuticalCoLTDMember", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:AgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - LICENSE AGREEMENT (Details Narrative)", "role": "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative", "shortName": "LICENSE AGREEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nbio:LicenseAgreementTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31_nbio_BioRayPharmaceuticalCoLTDMember", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:AgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2016-06-01to2016-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:ContingentSalesFeeDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2016-06-01to2016-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "nbio:ContingentSalesFeeDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2022-04-01to2022-04-04", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2022-06-03to2022-06-14", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2020-03-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)", "role": "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "AsOf2020-03-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:NetLossIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "nbio:NetLossIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS", "role": "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperations", "shortName": "ORGANIZATION AND NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://nascentbiotechinc.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - GOING CONCERN", "role": "http://nascentbiotechinc.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nbio_10k.htm", "contextRef": "From2021-04-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 45, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nascentbiotechinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "nbio_AccountPayableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Account payable, shares" } } }, "localname": "AccountPayableShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_AccruedCompensationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accrued consulting fees" } } }, "localname": "AccruedCompensationAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_AccruedFeesConvertedAmountIntoShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued fees converted amount, shares", "verboseLabel": "Accrued fees converted amount, shares" } } }, "localname": "AccruedFeesConvertedAmountIntoShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_AdditionalInvestmentOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Additional investment" } } }, "localname": "AdditionalInvestmentOther", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_AdditionalSharesEarnedToMaintainOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Shares Earned to Maintain Ownership Percentage" } } }, "localname": "AdditionalSharesEarnedToMaintainOwnershipPercentage", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "sharesItemType" }, "nbio_AdvanceFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Advance from related party" } } }, "localname": "AdvanceFromRelatedParty", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_AgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement description" } } }, "localname": "AgreementDescription", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "stringItemType" }, "nbio_AlphaHoldingIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alpha Holding Inc [Member]" } } }, "localname": "AlphaHoldingIncMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_AnnualMaintenance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Annual Maintenance" } } }, "localname": "AnnualMaintenance", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_AnnualMaintenanceFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Annual maintenance fee" } } }, "localname": "AnnualMaintenanceFee", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_AprilOneTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "April 1, 2018 [Member]" } } }, "localname": "AprilOneTwoThousandEighteenMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_AprilOneTwoThousandSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "April 1, 2017 [Member]" } } }, "localname": "AprilOneTwoThousandSeventeenMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_AprilOneTwoThousandSixteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "April 1, 2016 [Member]" } } }, "localname": "AprilOneTwoThousandSixteenMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_BalanceDue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Balance due" } } }, "localname": "BalanceDue", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_BioRayPharmaceuticalCoLTDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BioRay Pharmaceutical Co LTD [Member]" } } }, "localname": "BioRayPharmaceuticalCoLTDMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_BonusAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Bonus amount" } } }, "localname": "BonusAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_CashPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Cash]", "verboseLabel": "Cash" } } }, "localname": "CashPaid", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_ChangeInFairValueAtInitialIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in fair value at initial issuance" } } }, "localname": "ChangeInFairValueAtInitialIssuance", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "nbio_ChangeInFairValueDueToConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value due to conversion of debt" } } }, "localname": "ChangeInFairValueDueToConversionOfDebt", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "nbio_ChangeInFairValueOfTheDerivative": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of the derivative" } } }, "localname": "ChangeInFairValueOfTheDerivative", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "nbio_ChiefFinancialOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Financial Officers [Member]" } } }, "localname": "ChiefFinancialOfficersMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_ClinicalTrials": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Clinical trials" } } }, "localname": "ClinicalTrials", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "nbio_CommonSharesIssuedForSettlementOfAccountsPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common shares issued, for settlement of accounts payable" } } }, "localname": "CommonSharesIssuedForSettlementOfAccountsPayable", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockCancelledShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, shares cancelled" } } }, "localname": "CommonStockCancelledShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockExercisableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock exercisable term" } } }, "localname": "CommonStockExercisableTerm", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "durationItemType" }, "nbio_CommonStockForConversionOfPayablesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock for conversion of payables, amount" } } }, "localname": "CommonStockForConversionOfPayablesAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockForConversionOfPayablesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock for conversion of payables, shares" } } }, "localname": "CommonStockForConversionOfPayablesShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockForServiceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock for service, amount" } } }, "localname": "CommonStockForServiceAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockForServiceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock for service, shares" } } }, "localname": "CommonStockForServiceShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockIssuedForAccountsPayableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for accounts payable, amount" } } }, "localname": "CommonStockIssuedForAccountsPayableAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockIssuedForAccountsPayableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for accounts payable, shares" } } }, "localname": "CommonStockIssuedForAccountsPayableShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockIssuedForAccruedPayablesRelatedPartiesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock issued for accrued payables- related parties, amount" } } }, "localname": "CommonStockIssuedForAccruedPayablesRelatedPartiesAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockIssuedForAccruedPayablesRelatedPartiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for accrued payables- related parties, shares" } } }, "localname": "CommonStockIssuedForAccruedPayablesRelatedPartiesShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockIssuedForConvertibleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock issued for convertible debt" } } }, "localname": "CommonStockIssuedForConvertibleDebt", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockIssuedForConvertibleDebtAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for convertible debt, amount" } } }, "localname": "CommonStockIssuedForConvertibleDebtAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockIssuedForConvertibleDebtShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for convertible debt, shares" } } }, "localname": "CommonStockIssuedForConvertibleDebtShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockIssuedForServiceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for service, shares" } } }, "localname": "CommonStockIssuedForServiceShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockIssuedForTheConversionOfPreferredSharesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for the conversion of preferred shares, amount" } } }, "localname": "CommonStockIssuedForTheConversionOfPreferredSharesAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockIssuedForTheConversionOfPreferredSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for the conversion of preferred shares, shares" } } }, "localname": "CommonStockIssuedForTheConversionOfPreferredSharesShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockIssuedToRelatedPartiesForServiceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to related parties for service, amount" } } }, "localname": "CommonStockIssuedToRelatedPartiesForServiceAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockIssuedToRelatedPartiesForServiceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to related parties for service, shares" } } }, "localname": "CommonStockIssuedToRelatedPartiesForServiceShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock One [Member]" } } }, "localname": "CommonStockOneMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_CommonStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, price per share" } } }, "localname": "CommonStockPricePerShare", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "nbio_CommonStockSharesIssuedForCompensationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares issued for compensation, shares" } } }, "localname": "CommonStockSharesIssuedForCompensationShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockSharesIssuedForCompensationValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock shares issued for compensation, value" } } }, "localname": "CommonStockSharesIssuedForCompensationValue", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Three [Member]" } } }, "localname": "CommonStockThreeMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_CommonStockToRelatedPartiesForConversionOfPayablesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock to related parties for conversion of payables, shares" } } }, "localname": "CommonStockToRelatedPartiesForConversionOfPayablesShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockToRelatedPartiesForServiceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock to related parties for service, shares" } } }, "localname": "CommonStockToRelatedPartiesForServiceShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_CommonStockToRelatedPartiesForServiceamount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock to related parties for service, amount" } } }, "localname": "CommonStockToRelatedPartiesForServiceamount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_CommonStockTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Two [Member]" } } }, "localname": "CommonStockTwoMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_CommonstocktorelatedpartiesforconversionofpayablesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock to related parties for conversion of payables, amount" } } }, "localname": "CommonstocktorelatedpartiesforconversionofpayablesAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_ConsultingFeesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Consulting fees payable" } } }, "localname": "ConsultingFeesPayable", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_ContingentSalesFeeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contingent sales fee description" } } }, "localname": "ContingentSalesFeeDescription", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "nbio_ConvertibleDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible, description" } } }, "localname": "ConvertibleDescription", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "nbio_ConvertiblePreferredStockSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockSeriesAMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_DeemedDividendFromDownRound": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Deemed dividend from down round]", "verboseLabel": "Deemed dividend from down round" } } }, "localname": "DeemedDividendFromDownRound", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_DeemedDividendFromDownRoundAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deemed dividend from down round" } } }, "localname": "DeemedDividendFromDownRoundAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_DiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discount rate" } } }, "localname": "DiscountRate", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "nbio_EarningsPerSharesBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income (loss) per share, basic and diluted" } } }, "localname": "EarningsPerSharesBasicAndDiluted", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "nbio_EightPercentageConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "8% Convertible Note [Member]" } } }, "localname": "EightPercentageConvertibleNoteMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_ExercisePriceOrWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price of warrants" } } }, "localname": "ExercisePriceOrWarrants", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "nbio_FairValueOfOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value of option granted" } } }, "localname": "FairValueOfOption", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_FairValueOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of warrants" } } }, "localname": "FairValueOfWarrants", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_FinanceCosts": { "auth_ref": [], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Finance costs" } } }, "localname": "FinanceCosts", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "nbio_FinancingCost": { "auth_ref": [], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "[Financing cost]", "negatedLabel": "Financing cost" } } }, "localname": "FinancingCost", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nbio_FirstBLAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First BLA [Member]" } } }, "localname": "FirstBLAMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_FirstPhaseICinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Phase I clinical trial [Member]" } } }, "localname": "FirstPhaseICinicalTrialMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_FirstPhaseIIICinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Phase III clinical trial [Member]" } } }, "localname": "FirstPhaseIIICinicalTrialMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_FiscalYearAnnualizedCompensationBeingPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fiscal Year Annualized Compensation Being Paid" } } }, "localname": "FiscalYearAnnualizedCompensationBeingPaid", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "nbio_FourOfficersAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Four Officers and Director [Member]" } } }, "localname": "FourOfficersAndDirectorMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_FourOfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Four Officers And Directors [Member]" } } }, "localname": "FourOfficersAndDirectorsMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_FuturePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Future payments" } } }, "localname": "FuturePayments", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_GainsLossesOnExtinguishmentOfDebt1": { "auth_ref": [], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gain on debt forgiveness" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "nbio_InitialInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial investment" } } }, "localname": "InitialInvestment", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_InitialShareAwardsUnderContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Share Awards Under the Contracts" } } }, "localname": "InitialShareAwardsUnderContracts", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "sharesItemType" }, "nbio_InvestmentOptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price of options" } } }, "localname": "InvestmentOptionsExercisePrice", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "nbio_IssuanceOfLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of license agreement" } } }, "localname": "IssuanceOfLicenseAgreement", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_JinEnGroupInternationalHoldingCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jin-En [Member]" } } }, "localname": "JinEnGroupInternationalHoldingCompanyMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 11 - LICENSE AGREEMENT" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseAgreement" ], "xbrltype": "textBlockItemType" }, "nbio_MergerDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Merger, description" } } }, "localname": "MergerDescription", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "nbio_NetLossIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Net loss]", "negatedLabel": "Net loss" } } }, "localname": "NetLossIncome", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nbio_NetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net sales" } } }, "localname": "NetSales", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "durationItemType" }, "nbio_NonDilutiveSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-dilutive shares, percentage" } } }, "localname": "NonDilutiveSharesPercentage", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "nbio_NonMonetaryTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON MONETARY TRANSACTIONS" } } }, "localname": "NonMonetaryTransactionsAbstract", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "nbio_NumberOfInstallmentsRemainingLiability": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of installments, consideration for license" } } }, "localname": "NumberOfInstallmentsRemainingLiability", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative" ], "xbrltype": "integerItemType" }, "nbio_NumberOfInstallmentsVest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of installments vest" } } }, "localname": "NumberOfInstallmentsVest", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "integerItemType" }, "nbio_NumberOfWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of warrants" } } }, "localname": "NumberOfWarrantsAbstract", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "nbio_OfficerAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officer And Director [Member]" } } }, "localname": "OfficerAndDirectorMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_OfficersAndDirectorsEmploymentAgreementTermsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers and directors employment agreement terms, description" } } }, "localname": "OfficersAndDirectorsEmploymentAgreementTermsDescription", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "nbio_OptionOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option 1 [Member]" } } }, "localname": "OptionOneMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_OptionTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option 2 [Member]" } } }, "localname": "OptionTwoMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_OptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options" } } }, "localname": "OptionsAbstract", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "stringItemType" }, "nbio_OptionsVestedDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options vested description" } } }, "localname": "OptionsVestedDescription", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "nbio_OriginalIssueDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Original issue discount" } } }, "localname": "OriginalIssueDiscount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_OutstandingOptionForfeited": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Outstanding option, Forfeited]", "verboseLabel": "Outstanding option, Forfeited" } } }, "localname": "OutstandingOptionForfeited", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "monetaryItemType" }, "nbio_PreferredSharesIssuedForCashAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred shares issued for cash, amount" } } }, "localname": "PreferredSharesIssuedForCashAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_PreferredSharesIssuedForNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred shares issued for notes payable" } } }, "localname": "PreferredSharesIssuedForNotesPayable", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nbio_PreferredSharesIssuedForNotesPayableSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred shares issued for notes payable, shares" } } }, "localname": "PreferredSharesIssuedForNotesPayableSharesShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "nbio_PreferredStockIssuedForCashshares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred stock issued for cash, shares" } } }, "localname": "PreferredStockIssuedForCashshares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_PreferredStockShares1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred stock shares" } } }, "localname": "PreferredStockShares1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_PreferredStockSharesDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred stock shares designated" } } }, "localname": "PreferredStockSharesDesignated", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_PreferredsharesissuedfornotespayableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred shares issued for notes payable, amount" } } }, "localname": "PreferredsharesissuedfornotespayableAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "nbio_PresidentAndChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "President And Chief Executive Officer [Member]" } } }, "localname": "PresidentAndChiefExecutiveOfficerMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_ProceedsFromExerciseOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromExerciseOfWarrants", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_RepaidAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Repaid amount" } } }, "localname": "RepaidAmount", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_RepaymentOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Repayment of convertible notes]", "negatedLabel": "Repayment of convertible notes" } } }, "localname": "RepaymentOfConvertibleNotes", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nbio_RoyaltyRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty rate" } } }, "localname": "RoyaltyRate", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "percentItemType" }, "nbio_ScheduleOfAnnualSalaryAndAnnualSeveranceAmountsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of annual salary and annual severance amounts" } } }, "localname": "ScheduleOfAnnualSalaryAndAnnualSeveranceAmountsTableTextBlock", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "nbio_ScheduleOfSharesEarnedByRelatedPartyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of shares earned by related party" } } }, "localname": "ScheduleOfSharesEarnedByRelatedPartyTableTextBlock", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "nbio_ScheduleOfSummaryOfWarrantsOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are", "label": "Schedule of Summary of warrants outstanding" } } }, "localname": "ScheduleOfSummaryOfWarrantsOutstandingTableTextBlock", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "nbio_SeptemberOneTwoThousandFifteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 1, 2015 [Member]" } } }, "localname": "SeptemberOneTwoThousandFifteenMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_SeptemberOneTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 1, 2020 [Member]" } } }, "localname": "SeptemberOneTwoThousandTwentyMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_SevenPercentageConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "7% Convertible Note [Member]" } } }, "localname": "SevenPercentageConvertibleNoteMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding warrants, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingBeginning", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumberBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding option, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumberBeginning", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "sharesItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumberEnding1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding warrants, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumberEnding1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAbstract", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "stringItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average exercise price, Beginning]", "verboseLabel": "Weighted average exercise price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning3", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "perShareItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average exercise price, Ending]", "verboseLabel": "Weighted average exercise price, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "nbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceEnding", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "perShareItemType" }, "nbio_ShareBasedCompensationArrangementExpirationsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding warrants, Expired" } } }, "localname": "ShareBasedCompensationArrangementExpirationsInPeriod", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nbio_ShareBasedCompensationArrangementGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Outstanding warrants, granted]", "verboseLabel": "Outstanding warrants, granted" } } }, "localname": "ShareBasedCompensationArrangementGrantsInPeriodGross", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nbio_ShareBasedCompensationArrangementOutstandingNumberEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding option, Ending" } } }, "localname": "ShareBasedCompensationArrangementOutstandingNumberEnding", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "sharesItemType" }, "nbio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "nbio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "nbio_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "nbio_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptionsBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of option exercisable, Beginning" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptionsBeginning", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "sharesItemType" }, "nbio_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptionsEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of option exercisable, Ending" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptionsEnding", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "sharesItemType" }, "nbio_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingBeginning": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Intrinsic value, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingBeginning", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "monetaryItemType" }, "nbio_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingBeginning1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Intrinsic value, Beginning]", "verboseLabel": "Intrinsic value, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingBeginning1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "monetaryItemType" }, "nbio_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingEnding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Intrinsic value, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingEnding", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "monetaryItemType" }, "nbio_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingEnding1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Intrinsic value, Ending]", "verboseLabel": "Intrinsic value, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstandingEnding1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "monetaryItemType" }, "nbio_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Remaining Contract life, Beginning]", "verboseLabel": "Weighted Average Remaining Contract life, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "durationItemType" }, "nbio_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contract life, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "durationItemType" }, "nbio_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Remaining Contract life, Ending]", "verboseLabel": "Weighted Average Remaining Contract life, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding1", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "durationItemType" }, "nbio_StockIssuedDuringPeriodExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding warrants, Exercised" } } }, "localname": "StockIssuedDuringPeriodExercised", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nbio_SummarizesOfChangeInTheFairValueOfTheDerivativeLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Summarizes of change in the fair value of the derivative liabilities" } } }, "localname": "SummarizesOfChangeInTheFairValueOfTheDerivativeLiabilities", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "nbio_ThreeOfficersAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Officers and Director [Member]" } } }, "localname": "ThreeOfficersAndDirectorMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_ThreeOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Officers [Member]" } } }, "localname": "ThreeOfficersMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_TotalNoOfAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total no of authorized shares" } } }, "localname": "TotalNoOfAuthorizedShares", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_TotalSharesEarned": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Shares Earned" } } }, "localname": "TotalSharesEarned", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "sharesItemType" }, "nbio_TwoOfficersAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Officers and Director [Member]" } } }, "localname": "TwoOfficersAndDirectorMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_TwoOfficersAndDirectorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Officers and Director One [Member]" } } }, "localname": "TwoOfficersAndDirectorOneMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_VestPercentageAtGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vest percentage at grant" } } }, "localname": "VestPercentageAtGrant", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "nbio_WarrantsDescriptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants descriptions" } } }, "localname": "WarrantsDescriptions", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "nbio_WarrantsExercisedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrants exercised value" } } }, "localname": "WarrantsExercisedValue", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_WarrantsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants granted" } } }, "localname": "WarrantsGranted", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nbio_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nbio_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 8 - WARRANTS" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WARRANTS" ], "xbrltype": "textBlockItemType" }, "nbio_WeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average exercise price]", "verboseLabel": "Weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceAbstract", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "nbio_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "nbio_WeightedAverageRemainingContractLifeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contract Life", "verboseLabel": "Weighted Average Remaining Contract Life" } } }, "localname": "WeightedAverageRemainingContractLifeAbstract", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails", "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "nbio_WeightedAverageRemainingContractLifeGrantedOne": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contract life, Granted" } } }, "localname": "WeightedAverageRemainingContractLifeGrantedOne", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "durationItemType" }, "nbio_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nbio_advances": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Advances" } } }, "localname": "advances", "nsuri": "http://nascentbiotechinc.com/20220331", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief financial officer.", "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_InterestEarningAssetsNetYield": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Net yield on interest-earning assets calculated as difference between total interest earned and total interest paid divided by total interest-earning assets.", "label": "[Interest-Earning Assets, Net Yield]", "verboseLabel": "Interest rate" } } }, "localname": "InterestEarningAssetsNetYield", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "srt_MaximumMember": { "auth_ref": [ "r194", "r229", "r261", "r262", "r361", "r362", "r363", "r364", "r365", "r366", "r386", "r421", "r422", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r194", "r229", "r261", "r262", "r361", "r362", "r363", "r364", "r365", "r366", "r386", "r421", "r422", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of president.", "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r194", "r229", "r251", "r261", "r262", "r361", "r362", "r363", "r364", "r365", "r366", "r386", "r421", "r422", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r194", "r229", "r251", "r261", "r262", "r361", "r362", "r363", "r364", "r365", "r366", "r386", "r421", "r422", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS (Tables)" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expense" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r8", "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts payable" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r21", "r146", "r147" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r7", "r8", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued bonus", "verboseLabel": "Accrued interest" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedFeesAndOtherRevenueReceivable": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, the amount of fees and other revenue, excluding investment income receivable, earned but not yet received, which were recognized in conformity with revenue recognition criteria based on estimates or specific contractual terms.", "label": "Accrued fees" } } }, "localname": "AccruedFeesAndOtherRevenueReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r22", "r279", "r351" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r96", "r97", "r98", "r276", "r277", "r278", "r319" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvanceRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount at the balance sheet date that has been received by the entity that represents rents paid in advance.", "label": "Advanced payment" } } }, "localname": "AdvanceRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r62", "r73", "r214", "r337" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Original interest debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r89", "r131", "r134", "r140", "r154", "r177", "r178", "r179", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r308", "r311", "r327", "r349", "r351", "r402", "r412" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r44", "r89", "r154", "r177", "r178", "r179", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r308", "r311", "r327", "r349", "r351" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r266", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r29", "r351", "r428", "r429" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r13", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r75", "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents]", "periodEndLabel": "Cash - end of year", "periodStartLabel": "Cash - beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r69", "r328" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r86", "r89", "r108", "r109", "r110", "r112", "r113", "r117", "r118", "r119", "r154", "r177", "r182", "r183", "r184", "r188", "r189", "r227", "r228", "r231", "r235", "r327", "r444" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r248", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants conversion price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r175", "r406", "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r172", "r173", "r174", "r176", "r433" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "NOTE 12 - COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common stock shares value for account payable" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r96", "r97", "r319" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Exercise price" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, shares par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r351" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 500,000,000 authorized, 111,313,175 and 104,834,083 issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r82", "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principle of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock shares issued upon conversion of debt, amount" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock issued for accounts payable", "verboseLabel": "Common stock share issued for cash, amount" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock shares issued upon conversion of debt, shares", "verboseLabel": "Common stock shares issued upon conversion of debt" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock share issued for cash, shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r16", "r404", "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible debt", "verboseLabel": "Convertible note issued" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r190", "r191", "r192", "r194", "r204", "r205", "r206", "r210", "r211", "r212", "r213", "r214", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r16", "r404", "r413", "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible note- net of discount" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r18", "r19", "r238", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Conversion of preferred stock shares issued", "verboseLabel": "Conversion of preferred stock shares issued" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r78", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion, converted instrument, amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r78", "r80" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt conversion, converted instrument, shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion description", "verboseLabel": "Conversion price, Description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r78", "r80" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt discount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": { "auth_ref": [ "r78", "r80" ], "lang": { "en-us": { "role": { "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Interest rate" } } }, "localname": "DebtConversionOriginalDebtInterestRateOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r85", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r208", "r215", "r216", "r218", "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTE 10 - CONVERTIBLE DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r88", "r94", "r191", "r192", "r193", "r194", "r195", "r196", "r198", "r204", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r219", "r220", "r221", "r222", "r340", "r403", "r404", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r191", "r219", "r220", "r338", "r340", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt conversion, principle balance" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r39", "r194", "r323" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r40", "r88", "r94", "r191", "r192", "r193", "r194", "r195", "r196", "r198", "r204", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r219", "r220", "r221", "r222", "r340" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Monthly installment payment" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrant term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r294", "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "[Deferred Tax Assets, Valuation Allowance]", "negatedLabel": "Less: Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Settlemet of accounts payable" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r73", "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r45", "r48", "r49", "r315", "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "[Derivative Liability, Fair Value, Gross Liability]", "periodEndLabel": "Ending Balance", "periodStartLabel": "Begnning Balance" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r46", "r47", "r48", "r326" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPTIONS" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPTIONS (Details)" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r32", "r93", "r180", "r182", "r183", "r187", "r188", "r189", "r345" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due related parties", "verboseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r91", "r285", "r302" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r53", "r54", "r55", "r96", "r97", "r98", "r100", "r105", "r107", "r116", "r156", "r243", "r246", "r276", "r277", "r278", "r297", "r298", "r319", "r329", "r330", "r331", "r332", "r333", "r334", "r423", "r424", "r425", "r454" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r73", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value of common stock" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r206", "r219", "r220", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r322", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE AGREEMENT" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r206", "r252", "r253", "r258", "r260", "r322", "r358" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r206", "r219", "r220", "r252", "r253", "r258", "r260", "r322", "r359" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r206", "r219", "r220", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r322", "r360" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r206", "r219", "r220", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r149", "r150", "r151", "r152", "r153", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r217", "r241", "r318", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r444", "r445", "r446", "r447", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnForeignCurrencyFairValueHedgeDerivatives": { "auth_ref": [ "r314", "r316" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of foreign currency derivatives and nonderivative instruments designated as fair value hedging instruments which were recognized in earnings, net of offsets by the gain (loss) on the hedged item to the extent that the fair value hedge was determined to be effective.", "label": "[Gain (Loss) on Foreign Currency Fair Value Hedge Derivatives]", "negatedLabel": "Change in fair value of derivative liabilities" } } }, "localname": "GainLossOnForeignCurrencyFairValueHedgeDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r73", "r408" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain on change in fair value of derivative liabilities" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r73", "r223", "r224" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "[Gain (Loss) on Extinguishment of Debt]", "negatedLabel": "Gain on debt forgiveness" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE DEBT" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r90", "r301" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Domestic]", "totalLabel": "Net income (loss) before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r91", "r286", "r287", "r292", "r299", "r303", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "NOTE 9 - INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r92", "r106", "r107", "r130", "r284", "r300", "r304", "r419" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 14.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r52", "r282", "r283", "r287", "r288", "r291", "r296" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r72" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "[Increase (Decrease) in Accounts Receivable]", "verboseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r72" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Due to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableRelatedParties": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount owed by the reporting entry in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Common stock issued for payables - related parties" } } }, "localname": "IncreaseDecreaseInNotesPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r72" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "Prepaid" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r56", "r129", "r336", "r339", "r409" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r59" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r68", "r70", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE SETTLEMENT" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r89", "r135", "r154", "r177", "r178", "r179", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r309", "r311", "r312", "r327", "r349", "r350" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r89", "r154", "r327", "r351", "r405", "r416" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r38", "r89", "r154", "r177", "r178", "r179", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r309", "r311", "r312", "r327", "r349", "r350", "r351" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r10", "r11", "r12", "r16", "r17", "r89", "r154", "r177", "r178", "r179", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r309", "r311", "r312", "r327", "r349", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Net liablilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsDisclosureTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for life settlement contracts including the accounting policy for life settlement contracts and the classification of cash receipts and cash disbursements in the statement of cash flows and, as applicable, for (1) life settlement contracts accounted for under the investment method based on the remaining life expectancy for each of the first five succeeding years from the date of the statement of financial position and thereafter, as well as in the aggregate: (a) the number of life settlement contracts, (b) the carrying value of the life settlement contracts, and (c) the face value (death benefits) of the life insurance policies underlying the contracts, (d) the life insurance premiums anticipated to be paid for each of the five succeeding fiscal years to keep the life settlement contracts in force as of the date of the most recent statement of financial position presented, (e) the nature of the information that causes the Entity to change its expectations on the timing of the realization of proceeds from the investments in life settlement contracts and the related effect on the timing of the realization of proceeds from the life settlement contracts and for (2) life settlement contracts accounted for under the fair value method, disclosure would include, based on remaining life expectancy for each of the first five succeeding years from the date of the statement of financial position and thereafter, as well as in the aggregate: (a) the number of life settlement contracts, (b) the carrying value of the life settlement contracts, (c) the face value (death benefits) of the life insurance policies underlying the contracts, (d) the reasons for changes in the Entity's expectation of the timing of the realization of the investments in life settlement contracts, and (e) (i) the gains or losses recognized during the period on investments sold during the period and (ii) the unrealized gains or losses recognized during the period on investments that are still held at the date of the statement of financial position.", "label": "NOTE 5 - LICENSE SETTLEMENT" } } }, "localname": "LifeSettlementContractsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/LicenseSettlement" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by ( used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r71", "r74" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net provided by (cash used) in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r50", "r51", "r55", "r58", "r74", "r89", "r99", "r101", "r102", "r103", "r104", "r106", "r107", "r111", "r131", "r133", "r136", "r139", "r141", "r154", "r177", "r178", "r179", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r320", "r327", "r407", "r418" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "Net income loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations", "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": { "auth_ref": [ "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Issued options" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "negatedLabel": "Total operating expense" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r131", "r133", "r136", "r139", "r141" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "[Operating Loss Carryforwards]", "negatedLabel": "Federal net operating loss carry forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock": { "auth_ref": [ "r317", "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for freestanding contract indexed to and potentially settled in entity's own stock. Includes, but is not limited to, strike price and number of shares to which contract is indexed, settlement date, and settlement alternatives.", "label": "NOTE 7 - OPTIONS" } } }, "localname": "OptionIndexedToIssuersEquityDescriptionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OPTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND NATURE OF OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "[Other Accrued Liabilities, Current]", "verboseLabel": "Accrued interest" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r61", "r420" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "[Other Expenses]", "negatedLabel": "Other expense" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentNotReadilyMarketableDescription": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Description of the investment category or actual investment title.", "label": "Investment description" } } }, "localname": "OtherInvestmentNotReadilyMarketableDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r266", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r227" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, shares par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19", "r227" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19", "r351" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock Value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r27", "r28" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r65" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible note" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r64" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from the sale of preferred shares and warrants" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r65" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r431", "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Consulting expense", "terseLabel": "Consulting fees", "verboseLabel": "Consulting fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations", "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r30", "r171", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r259", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative", "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r259", "r344", "r346", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative", "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r342", "r343", "r345", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "NOTE 4 - RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Agreement from related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r281", "r387", "r438" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r31", "r168", "r169", "r438" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research and Development Expense" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r246", "r279", "r351", "r415", "r426", "r427" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r96", "r97", "r98", "r100", "r105", "r107", "r156", "r276", "r277", "r278", "r297", "r298", "r319", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r57", "r89", "r127", "r128", "r132", "r137", "r138", "r142", "r143", "r144", "r154", "r177", "r178", "r179", "r182", "r183", "r184", "r185", "r186", "r188", "r189", "r327", "r410" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GOING CONCERN" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Components of net deferred tax assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES (Tables)" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Outstanding warrants, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Schedule of Summary of stock options aoutstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": { "auth_ref": [ "r263", "r264", "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationForfeituresPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of option exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intrinsic value", "verboseLabel": "Intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails", "http://nascentbiotechinc.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r271", "r280" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contract life, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance", "verboseLabel": "Common stock, issued shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Warrants outstanding" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r18", "r19", "r20", "r86", "r89", "r108", "r109", "r110", "r112", "r113", "r117", "r118", "r119", "r154", "r177", "r182", "r183", "r184", "r188", "r189", "r227", "r228", "r231", "r235", "r243", "r327", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r42", "r53", "r54", "r55", "r96", "r97", "r98", "r100", "r105", "r107", "r116", "r156", "r243", "r246", "r276", "r277", "r278", "r297", "r298", "r319", "r329", "r330", "r331", "r332", "r333", "r334", "r423", "r424", "r425", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative", "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative", "http://nascentbiotechinc.com/role/OptionsDetailsNarrative", "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails", "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative", "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r96", "r97", "r98", "r116", "r388" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://nascentbiotechinc.com/role/ConvertibleDebtDetailsNarrative", "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/LicenseAgreementDetailsNarrative", "http://nascentbiotechinc.com/role/LicenseSettlementDetailsNarrative", "http://nascentbiotechinc.com/role/OptionsDetailsNarrative", "http://nascentbiotechinc.com/role/OrganizationAndNatureOfOperationsDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetails1", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetails", "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative", "http://nascentbiotechinc.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock shares issued for services, shares", "terseLabel": "Common stock value issued for services", "verboseLabel": "Common stock shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Preferred shares issued for cash, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the number of shares issued.", "label": "Common stock issued for retiring preferred shares" } } }, "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "[Shares Issued, Shares, Share-based Payment Arrangement, Forfeited]", "negatedLabel": "Outstanding option, Forfeited" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r243", "r246", "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Warrants exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r243", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Preferred stock shares, value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for service, amount", "terseLabel": "Common stock shares value for services, amount", "verboseLabel": "Common stock shares issued for services, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://nascentbiotechinc.com/role/EquityDetailsNarrative", "http://nascentbiotechinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock based compensation- related parties" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r24", "r25", "r89", "r148", "r154", "r327", "r351" ], "calculation": { "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity:", "verboseLabel": "Stockholders' deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheets", "http://nascentbiotechinc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r87", "r228", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r242", "r246", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "NOTE 6 - EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r335", "r353" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r335", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r335", "r353" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r352", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "NOTE 13 - SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "NOTE 3 - GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENT DISCLOSURES:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r149", "r150", "r151", "r152", "r153", "r217", "r241", "r318", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r444", "r445", "r446", "r447", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/OptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockRetiredParValueMethodAmount": { "auth_ref": [ "r20", "r243", "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.", "label": "Common stock shares value for account payable, amount" } } }, "localname": "TreasuryStockRetiredParValueMethodAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r120", "r121", "r122", "r123", "r124", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nascentbiotechinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "325", "URI": "http://asc.fasb.org/subtopic&trid=2197121" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(m)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r321": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/subtopic&trid=2229355" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "820", "Subparagraph": "(a)", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r439": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r441": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r442": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r443": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r444": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r445": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r446": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r447": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r448": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r449": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r450": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r451": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r452": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r453": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" }